Study of an Investigational Drug in Cancer Patients Whose Tumors Have FGFR Mutation

What we are studying

Researchers want to know if the study drug is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Adults diagnosed with a solid tumor or blood cancer that has been identified as having an FGFR mutation
  • Must have received at least one prior treatment for their disease
  • Must have progressive disease and in need of treatment

What is involved

  • Genetic testing once for study entry
  • Physical exams every month
  • Blood testing every 2 weeks for the first month and then every month
  • Eye exam
  • Electrocardiogram (ECG) every month
  • Echocardiogram
  • CT scans or MRI every 8 weeks
  • Depending on solid tumor may also have: CA-125 and/or PSA every 8 weeks; Lymphoma patients will have PET Scan
  • Bone marrow and SPEP every 8 weeks; Multiple Myeloma will also have Bone Marrow
  • Leukemia patients will have additional labs at each visit and Bone Marrow

Compensation

The Comprehensive Cancer Center will provide a parking voucher for study related visits.

Contact Information

Study Coordinator
R. Timothy Meares
Email
rmeares@wakehealth.edu
Phone
336-713-7748
Principal Investigator
Glenn Lesser, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.